Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BZ019 in R/R CD19+ B-cell Lymphoma
NCT04067414Phase 1Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2018
- Primary completion
- Jun 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of BZ019 in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), transformed B-cell lymphoma and 1 more, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Number of adverse events at 1 year. Started Jun 2018; status: completed.
02
Drugs
BZ019
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)transformed B-cell lymphomaprimary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT04067414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04067414.